Generic Biosimilar Medicines Association

Making Medicines Affordable

  • Home
  • About GBMA
    • Contact us
    • GBMA Members
    • Guiding principles
    • Code of Practice
      • Code Complaint Committee
      • Event Reporting
        • Educational Events
        • Non-Price Benefit Reports
      • Annual Review
        • 2011
        • 2012
        • 2013
        • 2014
        • 2015
        • 2016
        • 2017
        • 2018
      • Lodging a complaint
    • Media Enquiries
    • Our Objectives
    • Links
  • Advocacy
    • Extended Strategic Agreement
    • Generic Medicines Working Group (GMWG)
    • Submissions
  • Generics
    • Facts and Fallacies
    • Key Figures on Generic Medicines
    • What is a Generic Medicine?
    • Bioequivalence Explained
  • Biosimilars
    • GBMA Position on Biosimilars
      • Impact of Biosimilars
      • Switching
      • Pharmacy Substitution
      • Regulation
      • Awareness and Uptake
      • Naming
    • Key Figures on Biosimilars
  • Topics
    • IGBA
    • Price Disclosure
    • Intellectual Property
    • International Trade Agreements
  • News
    • News 2019
    • News 2018
    • News 2017
    • News 2016
    • News 2015
    • News 2014
  • GBMA Education
You are here: Home / Latest news / News 2017 / Pharmaceutical IP reform welcomed however complex issues remain

Pharmaceutical IP reform welcomed however complex issues remain

August 28, 2017 By Emilia

28 August 2017

Support from the Australian Government to raise the quality of pharmaceutical patents, as outlined in its response to the Productivity Commission inquiry into intellectual property arrangements, is welcomed by the Generic and Biosimilar Medicines Association (GBMA).

GBMA specifically welcomes the Government’s decision to further define the inventive step which will improve patent quality and align with international best practice, as well as a decision to abolish the failed innovation patent system.

“GBMA remains highly supportive of genuine innovation and the use of patents to encourage the discovery of new medical treatments. Intellectual property protection should be firmly focussed at the cutting edge of innovation and not merely used as a commercial strategy to deny market entry for competitors,” GBMA CEO, Belinda Wood said.

“GBMA has long advocated for action to redress the imbalance in Australia’s pharmaceutical patent system, and this is not the first inquiry to recommend significant reform to pharmaceutical intellectual property in Australia,”

“That many of the recommendations made by the Productivity Commission reflect similar reform proposals from other inquiries including the 2012 Raising the Bar Initiative, the 2013 Pharmaceutical Patents Review, and the 2015 ACIP Innovation Patent System Review, tells us there are clearly issues that need to be addressed,”

“However, it is also clear the Government recognises the complexity of implementing significant intellectual property reform, particularly as it relates to extension of patent terms and international trade agreements,”

“GBMA therefore stands ready to work with the Government and the broader medicines sector through the next consultation phase. We look forward to discussing ways to improve the patent system and navigate a sensible way forward that balances access to new innovations whilst ensuring affordable medicines for all Australians.” said Ms Wood.

 

– ENDS –

 

Filed Under: News 2017

Our Members

Juno
Juno
Sandoz logo
Sandoz logo
Mylan
Mylan
Arrow logo
Arrow logo
apotex
apotex
Celltrion Healthcare
Celltrion Healthcare
Fresnius Kabi
Fresnius Kabi
Fresnius Kabi
generic_partners
generic_partners
southern_cross
southern_cross
commercial_eyes
commercial_eyes
iqvia
iqvia
sinapse
sinapse

Generic Medicines: The Facts

Generic Medicines Facts

Generic medicines are quality medicines at affordable prices. Ask your doctor to prescribe a generic medicine, or ask for a generic medicine next time you take your prescription to the pharmacy. … More…

The promise of Biosimilars

Biosimilars

https://youtu.be/sBDur7xa084   Biosimilars provide a unique opportunity to help manage the growing costs of biological medicines on the PBS. They offer therapeutically equivalent and … More…

GBMA welcomes Fresenius Kabi Australia

October 4, 2019

4 October 2019 Canberra, ACT Canberra: Australia’s peak body representing generic and biosimilar manufacturers, the Generic and … More...

Federal Health Minister, Greg Hunt MP encourages healthcare sector to embrace biosimilar medicines.

October 2, 2019

2 October 2019 Doctors, pharmacists, medical researchers, and hospital leaders attend 'Your … More...

GBMA welcomes new appointment to the Board

September 30, 2019

30 September 2019 Canberra, ACT The nation’s peak body for generic and biosimilar … More…

© 2019 Generic Medicines Industry Association Pty Ltd | Site Map | Contact Us